In the last years, PSMA-PET imaging and multiparametric MRI (mpMRI) have improved the
clinical management of prostate cancer (PCa) patients. Currently, mpMRI is recommended …

Today, contrast-enhanced magnetic resonance imaging (MRI) is the imaging modality
recommended as the first-line test by international guidelines for primary detection and …

Over the last years, prostate magnetic resonance imaging (MRI) has gained a key role in the
primary diagnosis of clinically significant prostate cancer (csPCa). While a negative MRI can …

Prostate-specific membrane antigen (PSMA) is a highly expressed protein in prostate cancer
(PCa) and has become an increasingly popular target for molecular imaging in recent years …

Multiparametric MRI (mpMRI) is validated for the diagnosis of clinically significant prostate
cancer (csPCa). 68Ga-PSMA-11 PET/CT (68Ga-PSMA PET/CT) combined with mpMRI has …

Despite the developments of the last few years, metastatic castration-resistant prostate
cancer (PC) remains a deadly disease. Until recently, almost all guidelines recommended …

Introduction Clinical and biochemical assessment and biopsies can miss clinically
significant prostate cancers (csPCa) in up to 20% of patients and diagnose clinically …

Simple Summary Prostate cancer diagnosis and treatment options have rapidly improved
over the last few years. A growing number of publications have moved to front the utilization …

Purpose Positron emission tomography (PET) for prostate-specific membrane antigen
(PSMA) represents a promising method for prostate cancer diagnosis and staging …

Purpose Multiparametric MRI (mpMRI) has been promoted as an auxiliary diagnostic tool for
prostate biopsy. However, prostate-specific membrane antigen (PSMA) including 68 Ga …